ConferencePoster
 (2023)

KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer

Monk, Bradley J; Colombo, Nicoletta; Tewari, Krishnansu Sujata; Dubot, Coraline; Caceres, M Valeria; Hasegawa, Kosei; Shapira-Frommer, Ronnie; Salman, Pamela; Yañez, Eduardo; Gumus, Mahmut et al